Generalized Pustular Psoriasis Gpp clinical trials

Explore recruiting generalized pustular psoriasis gpp clinical trials.

Recruiting generalized pustular psoriasis gpp studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Generalized Pustular Psoriasis Gpp trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Effisayil® REP: An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis (GPP) presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v.

France, Germany, Italy, Spain, Belgium

Phase III and phase IV (Integrated) EU CTIS Study details

EffisayilTM ON: An open-label, long term extension study to assess the safety and efficacy of spesolimab treatment in patients with Generalized Pustular Psoriasis (GPP)

France, Italy, Germany, Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Generalized Pustular Psoriasis Gpp trials by city

Generalized Pustular Psoriasis Gpp clinical trials

Recruiting generalized pustular psoriasis gpp studies right now

Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

Picankibart in Palmoplantar Pustulosis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Also recruiting in Europe

EffisayilTM ON: An open-label, long term extension study to assess the safety and efficacy of spesolimab treatment in patients with Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis Gpp trials by city

Other conditions